Skip to main content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Office of Science and Data Policy (SDP)

The Office of Science and Data Policy is the departmental focal point for policy research, analysis, evaluation, and coordination of department-wide public health science policy and data policy activities and issues. The Office provides authoritative advice and analytical support to the ASPE and departmental leadership on public health science policy and data policy issues and initiatives, coordinates science and data policy issues of interagency scope within HHS, and manages interagency initiatives in science policy and data policy. The Office works closely with staff from across the Department on strategic plan development and implementation efforts. The Offices also carries out a program of policy research, analysis, evaluation, and data development in these issues.

The Office of Science and Data Policy includes several components:

Topic Areas:

  • HHS Data Council
  • Regulatory Impact Analysis
  • Strategic Planning
  • Information Quality Guidelines
  • Prevention and wellness
  • Public health systems and functions
  • Food safety and nutrition
  • Drugs and devices
  • Tobacco control and prevention
  • Biomedical research and development
  • Economic analysis
  • Emergency preparedness, response, and recovery
  • Data and statistical policy
  • Health disparities and vulnerable populations
  • Health information technology
  • Microsimulation
  • Privacy policy

Reports

Displaying 11 - 20 of 99. 10 per page. Page 2.

Advanced Search

Costs and Benefits of Selected Policy Tools to Promote Drug Development

February 15, 2018
The development of new drugs and biologics is critical to ensuring that the U.S. population continues to enjoy improvements in quality and length of life.

Estimating Medical Costs for Regulatory Benefit-Cost Analysis: Conceptual Framework and Best Practices

December 12, 2017
The U.S. Department of Health and Human Services (HHS) is required to assess the benefits and costs of its major regulations prior to promulgation. To support these assessments, in 2016 HHS issued its Guidelines for Regulatory Impact Analyses, developed under the leadership of its Office of the Assistant Secretary for Planning and Evaluation and its Department-wide Analytics Team.

Valuing Time in U.S. Department of Health and Human Services Regulatory Impact Analyses: Conceptual Framework and Best Practices

September 17, 2017
Executive Order 12866, as supplemented by Executive Orders 13563 and 13771, requires that most U.S. government agencies assess the costs, benefits, and other impacts of their major regulations before they are promulgated. Under the leadership of its Office of the Assistant Secretary for Planning and Evaluation, the U.S.

Analysis Report: Understanding the Role of Partnerships in Medical Product Development

July 26, 2017
Partnerships involving public sector organizations, academia, non-profits, and pharmaceutical companies have demonstrated their potential for addressing unmet needs in medical product research and development (R&D). Effective partnerships can enhance access to innovation, reduce risk, manage costs, and may provide a means for steering R&D investment to address societal objectives.

Final Report Volume I: Background Paper, Declining Response Rates in Federal Surveys: Trends and Implications

January 18, 2017
Over the last decade, survey response rates have been steadily declining, and this decline has raised concerns across the federal government regarding the quality and utility of national survey data.

Measurement of Interoperable Electronic Health Care Records Utilization

January 17, 2017
The objective of this project was to develop methods to measure the degree of interoperability as a result of data sharing and use between users of certified technologies who are eligible for Meaningful Use (MU) incentives and non-incentivized Trading Partners (TPs) using non-certified technologies.

Guidelines For Regulatory Impact Analysis: A Primer

January 12, 2017
Regulatory impact analyses (RIAs) apply a well-established and widely-used framework for collecting, organizing, and evaluating data on the anticipated consequences of alternative policies.

Guidelines For Regulatory Impact Analysis

January 12, 2017
Regulatory impact analyses (RIAs) apply a well-established and widely-used framework for collecting, organizing, and evaluating data on the anticipated consequences of alternative policies.

Study of Costs Associated with Community Activities under the Communities Putting Prevention to Work (CPPW) Initiative

March 24, 2016
The Centers for Disease Control and Prevention’s (CDC’s) Communities Putting Prevention to Work (CPPW) program funded 44 communities and states under the American Recovery and Reinvestment Act (ARRA) to implement community-based tobacco and obesity prevention interventions.

Observations on Trends in Prescription Drug Spending

March 7, 2016
Key findings • Expenditures on prescription drugs are rising and are projected to continue to rise faster than overall health spending thereby increasing this sector’s share of health care spending.